GENFIT Share Price Deutsche Boerse AG
Stocks
XUP
FR0004163111
Biotechnology & Medical Research
OTC Markets Traded|
Real-time Estimate
Tradegate
11:49:45 20/08/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 14.09 EUR | +3.30% |
|
+10.46% | +173.78% |
| 03/07 | Genfit soars on news of U.S. reimbursement for a product |  |
| 03/07 | Genfit's Liver Disease Blood Test Approved for US Medicare Reimbursement | MT |
| Market Cap | 72Cr 84Cr 67Cr 62Cr 115.88Cr 8.05TCr 118.17Cr 797.32Cr 310.81Cr 4.03TCr 315.9Cr 309.03Cr 13TCr | P/E 2026 * |
37.2x | P/E 2027 * | 95.6x |
|---|---|---|---|---|---|
| Enterprise Value | 67Cr 78Cr 62Cr 57Cr 107.66Cr 7.48TCr 109.78Cr 740.74Cr 288.76Cr 3.75TCr 293.49Cr 287.1Cr 12TCr | EV / Sales 2026 * |
6.68x | EV / Sales 2027 * | 5.27x |
| Free-Float |
86.89% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | +3.30% | ||
| 1 week | +10.46% | ||
| Current month | +2.43% | ||
| 1 month | +12.72% | ||
| 3 months | +71.57% | ||
| 6 months | +76.52% | ||
| Current year | +173.78% |
| 1 week | 12.94 |  | 14.36 |
| 1 month | 12.72 | | 14.86 |
| Current year | 5.08 | | 14.86 |
| 1 year | 3.01 | | 14.86 |
| 3 years | 2.8 | | 14.86 |
| 5 years | 2.74 | | 14.86 |
| 10 years | 2.74 | | 33.76 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Prigent
CEO | Chief Executive Officer | 58 | 16/09/2019 |
Thomas Baetz
DFI | Director of Finance/CFO | 52 | 22/04/2021 |
Pejvack Motlagh
CTO | Chief Tech/Sci/R&D Officer | - | 27/11/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | 16/06/2017 | |
| Director/Board Member | 54 | 15/09/1999 | |
| Director/Board Member | 58 | 16/06/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +3.30% | +10.46% | - | - | 84Cr | |
| +1.14% | +2.27% | +2.38% | +24.66% | 5.05TCr | |
| -1.41% | +4.23% | +482.26% | +604.87% | 4.6TCr | |
| -1.07% | +4.79% | +20.60% | +90.22% | 4.28TCr | |
| +3.82% | +7.22% | +34.85% | +20.81% | 4.1TCr | |
| 0.00% | -3.91% | +17.87% | +47.98% | 3.2TCr | |
| +1.98% | +6.62% | +33.23% | +152.26% | 1.7TCr | |
| -1.08% | +4.13% | - | - | 1.71TCr | |
| +3.06% | +3.88% | +5.81% | +35.45% | 1.43TCr | |
| +2.07% | +5.01% | +85.09% | +47.01% | 1.38TCr | |
| Average | +1.20% | +2.01% | +85.26% | +127.91% | 3.05TCr | |
| Weighted average by Cap. | +0.75% | +2.37% | +104.91% | +151.72% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 10Cr 12Cr 9.35Cr 8.58Cr 16Cr 1.12TCr 16Cr 110.9Cr 43Cr 561.17Cr 44Cr 43Cr 1.86TCr | 12Cr 14Cr 12Cr 11Cr 20Cr 1.39TCr 20Cr 137.3Cr 54Cr 694.75Cr 54Cr 53Cr 2.3TCr |
| Net income | 2.29Cr 2.67Cr 2.13Cr 1.96Cr 3.68Cr 255.67Cr 3.75Cr 25Cr 9.87Cr 128.13Cr 10Cr 9.81Cr 424.2Cr | 68L 79.42L 63.45L 58.22L 1.09Cr 76Cr 1.12Cr 7.53Cr 2.93Cr 38Cr 2.98Cr 2.92Cr 126.09Cr |
| Net Debt | -5.11Cr -5.97Cr -4.77Cr -4.38Cr -8.22Cr -571.26Cr -8.39Cr -57Cr -22Cr -286.29Cr -22Cr -22Cr -947.82Cr | -6.62Cr -7.73Cr -6.17Cr -5.67Cr -11Cr -739.52Cr -11Cr -73Cr -29Cr -370.62Cr -29Cr -28Cr -1.23TCr |
| Date | Price | Change |
|---|---|---|
| 20/26/20 | €14.36 | +5.28% |
| 19/26/19 | €13.64 | -0.73% |
| 18/26/18 | €13.74 | +6.18% |
| 17/26/17 | €12.94 | -2.85% |
| 14/26/14 | €13.32 | +2.46% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- GNFT Stock
- XUP Stock
Select your edition
All financial news and data tailored to specific country editions
